Get the Stockscreener App
0.709
2.74%
0.0189
After Hours:
.71
0.001
+0.14%
Tiziana Life Sciences Ltd Stock (TLSA) Latest News
Tiziana Life Sciences says foralumab shows promise in Alzheimer’s treatment - Proactive Investors
Tiziana Life Sciences Announces TV Interview with First Patient Dosed with Moderate Alzheimer’s Disease - GlobeNewswire
Tiziana Life Sciences Ltd (NASDAQ:TLSA) Sees Large Drop in Short Interest - MarketBeat
Tiziana Life Sciences Faces Nasdaq Compliance Challenge - MSN
Tiziana Life Sciences Ltd (NASDAQ:TLSA) Short Interest Update - MarketBeat
Tiziana Life Sciences (NASDAQ:TLSA) Stock Quotes, Forecast and News Summary - Benzinga
Short Interest in Tiziana Life Sciences Ltd (NASDAQ:TLSA) Drops By 21.4% - Defense World
Tiziana Life Sciences (FRA:0RP) Total Liabilities : €8.46 Mil (As of Jun. 2024) - GuruFocus.com
Tiziana Life Sciences Ltd (NASDAQ: TLSA) Jumps 11.06%: What Could Be On The Way Going Forward? - Stocks Register
Tiziana Life Sciences Announces Positive Results in Treating Spinal Cord Injury With Nasal Anti-CD3 - The Manila Times
Tiziana reports progress in spinal cord injury treatment - MSN
Tiziana reports progress in spinal cord injury treatment By Investing.com - Investing.com Australia
Tiziana Life Sciences reports promising preclinical results for nasal anti-CD3 in spinal cord injury - Proactive financial news
Tiziana's Nasal Treatment Shows Promise for Spinal Cord Injury Recovery in Breakthrough Study - StockTitan
Neurology-Focused Tiziana Life Confirms Discovery In Multiple Sclerosis Therapy Study - Benzinga
Tiziana Life Sciences not to engage in capital raising activities for the immediate future - The Manila Times
Tiziana Life Sciences Halts Capital Raising Plans After Promising MS Treatment Biomarker Discovery - StockTitan
Tiziana Life Sciences pauses capital raising activities - Proactive Investors USA
Tiziana Life Sciences identifies new immune biomarkers in MS patients treated with foralumab - Proactive Investors UK
Tiziana Life Sciences Announces Discovery of New Immune Biomarkers in Multiple Sclerosis Patients Treated with Nasal Foralumab - The Manila Times
Tiziana Life Sciences Reveals Breakthrough Biomarkers in Multiple Sclerosis Treatment Study - StockTitan
Tiziana Life Sciences Ltd (NASDAQ:TLSA) Sees Significant Growth in Short Interest - MarketBeat
3 Penny Stocks In US With Market Caps Below $300M - Simply Wall St
Tiziana Life Sciences’ foralumab reduces side effects of discontinuing GLP-1 agonists - Proactive financial news
Tiziana reports progress in immunotherapy treatment - Investing.com India
Tiziana Announces Reduction of Side Effects Commonly Seen with Discontinuation of GLP-1 Agonists with Nasal Anti-CD3 - The Manila Times
Tiziana's Breakthrough Nasal Therapy Enhances GLP-1 Drug Benefits, Reduces Side Effects - StockTitan
Tiziana’s foralumab shows promise in neurodegenerative diseases By Investing.com - Investing.com Nigeria
Tiziana's foralumab shows promise in neurodegenerative diseases By Investing.com - Investing.com Canada
Tiziana Life Sciences welcomes publication of article highlighting foralumab’s potential in neurological diseases - Proactive Investors UK
Tiziana's foralumab shows promise in neurodegenerative diseases - Investing.com India
Tiziana Life Sciences Announces Review Article Published in Nature Highlighting Foralumab's Potential in the Treatment of Neurological Disease - The Manila Times
Tiziana's Foralumab Shows Breakthrough Potential for Multiple Sclerosis in Nature Reviews Study - StockTitan
US Stocks Poised To Open Higher As Futures Advance: Tesla, Bumble, Lifecore Bio In Focus - Benzinga
Tiziana Life Sciences Ltd (NASDAQ:TLSA) Sees Large Decline in Short Interest - MarketBeat
Now Is The Time To Build A Position In Tiziana Life Sciences Ltd (NASDAQ:TLSA) - Marketing Sentinel
Tiziana Life Sciences: Awaiting Data Of Foralumab For Secondary Progressive Multiple Sclerosis - Seeking Alpha
2025 biotech outlook: Small-cap innovators tackling chronic and rare diseases - Proactive Investors Australia
Sanctuary Advisors LLC Makes New $864,000 Investment in Tiziana Life Sciences Ltd (NASDAQ:TLSA) - MarketBeat
Tiziana Life Sciences doses first Alzheimer’s patient with intranasal foralumab - Proactive Investors Australia
Tiziana Life Sciences Announces First Patient with Moderate Alzheimer's Disease Dosed with Intranasal Foralumab - The Manila Times
Tiziana Life Sciences Launches Novel Alzheimer's Treatment Trial with Groundbreaking Intranasal Therapy - StockTitan
3 US Penny Stocks With Market Caps Under $200M To Consider - Simply Wall St
17% Gain Today – This Stock Isn’t Done Yet - RagingBull
Tiziana Life Sciences expands Phase 2 trial for non-active SPMS - Yahoo Finance
Tiziana broadens Phase 2 trial for MS therapy By Investing.com - Investing.com Canada
U.S. Dollar Index (DXY) QuotePress Release - The Globe and Mail
2.27%
5.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):